IRWD vs. LGND, MNKD, DVAX, OPK, CYRX, ZNTL, IGMS, LXRX, GERN, and FOLD
Should you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include Ligand Pharmaceuticals (LGND), MannKind (MNKD), Dynavax Technologies (DVAX), OPKO Health (OPK), Cryoport (CYRX), Zentalis Pharmaceuticals (ZNTL), IGM Biosciences (IGMS), Lexicon Pharmaceuticals (LXRX), Geron (GERN), and Amicus Therapeutics (FOLD). These companies are all part of the "pharmaceutical preparations" industry.
Ironwood Pharmaceuticals (NASDAQ:IRWD) and Ligand Pharmaceuticals (NASDAQ:LGND) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.
Ligand Pharmaceuticals received 27 more outperform votes than Ironwood Pharmaceuticals when rated by MarketBeat users. Likewise, 69.92% of users gave Ligand Pharmaceuticals an outperform vote while only 61.04% of users gave Ironwood Pharmaceuticals an outperform vote.
Ironwood Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Ligand Pharmaceuticals has a net margin of 37.80% compared to Ironwood Pharmaceuticals' net margin of -226.37%. Ligand Pharmaceuticals' return on equity of 11.98% beat Ironwood Pharmaceuticals' return on equity.
91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 13.1% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Ironwood Pharmaceuticals presently has a consensus target price of $19.80, indicating a potential upside of 140.88%. Ligand Pharmaceuticals has a consensus target price of $116.33, indicating a potential upside of 62.89%. Given Ironwood Pharmaceuticals' higher possible upside, research analysts plainly believe Ironwood Pharmaceuticals is more favorable than Ligand Pharmaceuticals.
In the previous week, Ironwood Pharmaceuticals had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 5 mentions for Ironwood Pharmaceuticals and 2 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.17 beat Ironwood Pharmaceuticals' score of 0.11 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.
Ligand Pharmaceuticals has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Ligand Pharmaceuticals beats Ironwood Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Ironwood Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ironwood Pharmaceuticals Competitors List
Related Companies and Tools
